COVID-19 Vaccine-Related Vogt–Koyanagi–Harada Disease Complicated by Central Serous Chorioretinopathy during Treatment Course: Case Report and Literature Review
Abstract
:1. Introduction
2. Case Report
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Teijaro, J.; Farber, D. COVID-19 vaccines: Modes of immune activation and future challenges. Nat. Rev. Immunol. 2021, 21, 195–197. [Google Scholar] [CrossRef] [PubMed]
- Lin, W.; Wang, J.; Lai, C. Non-Arteritic Anterior Ischemic Optic Neuropathy Following COVID-19 Vaccination. Vaccines 2022, 10, 931. [Google Scholar] [CrossRef]
- Bolletta, E.; Iannetta, D.; Mastrofilippo, V.; de Simone, L.; Gozzi, F.; Croci, S.; Bonacini, M.; Belloni, L.; Zerbini, A.; Adani, C.; et al. Uveitis and Other Ocular Complications Following COVID-19 Vaccination. J. Clin. Med. 2021, 10, 5960. [Google Scholar] [CrossRef] [PubMed]
- Ding, X.; Chang, Q. Probable Vogt-Koyanagi-Harada Disease after COVID-19 Vaccination: Case Report and Literature Review. Vaccines 2022, 10, 783. [Google Scholar] [CrossRef]
- Haseeb, A.; Solyman, O.; Abushanab, M.; Abo Obaia, A.; Elhusseiny, A. Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective. Vaccines 2022, 10, 342. [Google Scholar] [CrossRef]
- Read, R.; Holland, G.; Rao, N.; Tabbara, K.; Ohno, S.; Arellanes-Garcia, L.; Pivetti-Pezzi, P.; Tessler, H.; Usui, M. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: Report of an international committee on nomenclature. Am. J. Ophthalmol. 2001, 131, 647–652. [Google Scholar] [CrossRef]
- Koong, L.; Chee, W.; Toh, Z.; Ng, X.; Agrawal, R.; Ho, S. Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine. Ocul. Immunol. Inflamm. 2021, 29, 1212–1215. [Google Scholar] [CrossRef] [PubMed]
- Reddy, Y.; Pandey, A.; Ojha, A.; Ramchandani, S. Harada-like syndrome post-Covishield vaccination: A rare adverse effect. Indian J. Ophthalmol. 2022, 70, 321–323. [Google Scholar] [CrossRef]
- De Domingo, B.; López, M.; Lopez-Valladares, M.; Ortegon-Aguilar, E.; Sopeña-Perez-Argüelles, B.; Gonzalez, F. Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine. Cells 2022, 11, 1012. [Google Scholar] [CrossRef]
- Chen, X.; Li, X.; Li, H.; Li, M.; Gong, S. Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen. Vaccines 2022, 10, 482. [Google Scholar] [CrossRef]
- Naranjo, C.; Busto, U.; Sellers, E.; Sandor, P.; Ruiz, I.; Roberts, E.; Janecek, E.; Domecq, C.; Greenblatt, D. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981, 30, 239–245. [Google Scholar] [CrossRef] [PubMed]
- Papasavvas, I.; Herbort, C. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination. J. Ophthalmic Inflamm. Infect. 2021, 11, 21. [Google Scholar] [CrossRef] [PubMed]
- Saraceno, J.; Souza, G.; Dos Santos Finamor, L.; Nascimento, H.; Belfort, R. Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine. Int. J. Retin. Vitr. 2021, 7, 49. [Google Scholar] [CrossRef] [PubMed]
- Watad, A.; David, P.; Brown, S.; Shoenfeld, Y. Autoimmune/Inflammatory Syndrome Induced by Adjuvants and Thyroid Autoimmunity. Front. Endocrinol. 2016, 7, 150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kakarla, P.; Venugopal, R.; Manechala, U.; Rijey, J.; Anthwal, D. Bilateral multifocal choroiditis with disc edema in a 15-year-old girl following COVID-19 vaccination. Indian J. Ophthalmol. 2022, 70, 3420–3422. [Google Scholar] [CrossRef] [PubMed]
- Du, L.; Kijlstra, A.; Yang, P. Vogt-Koyanagi-Harada disease: Novel insights into pathophysiology, diagnosis and treatment. Prog. Retin. Eye Res. 2016, 52, 84–111. [Google Scholar] [CrossRef]
- Lai, T.; Chan, R.; Chan, C.; Lam, D. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye 2009, 23, 543–548. [Google Scholar] [CrossRef] [Green Version]
- Read, R.; Yu, F.; Accorinti, M.; Bodaghi, B.; Chee, S.; Fardeau, C.; Goto, H.; Holland, G.; Kawashima, H.; Kojima, E.; et al. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am. J. Ophthalmol. 2006, 142, 119–124. [Google Scholar] [CrossRef]
- Yang, P.; Ren, Y.; Li, B.; Fang, W.; Meng, Q. Kijlstra A Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology 2007, 114, 60s6–614. [Google Scholar] [CrossRef]
- Mudie, L.; Zick, J.; Dacey, M. Palestine A Panuveitis following Vaccination for COVID-19. Ocul. Immunol. Inflamm. 2021, 29, 741–742. [Google Scholar] [CrossRef]
- Liu, X.; Yang, P.; Lin, X.; Ren, X.; Zhou, H.; Huang, X.; Chi, W.; Kijlstra, A.; Chen, L. Inhibitory effect of Cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin. Immunol. 2009, 131, 333–342. [Google Scholar] [CrossRef]
- Oo, E.E.L.; Chee, S.-P.; Wong, K.K.Y.; Htoon, H.M. Vogt-Koyanagi-Harada Disease Managed with Immunomodulatory Therapy Within 3 Months of Disease Onset. Am. J. Ophthalmol. 2020, 220, 37–44. [Google Scholar]
- Urzua, C.; Velasquez, V.; Sabat, P.; Berger, O.; Ramirez, S.; Goecke, A.; Vásquez, D.; Gatica, H.; Guerrero, J. Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2015, 93, e475–e480. [Google Scholar] [CrossRef] [Green Version]
- Paredes, I.; Ahmed, M.; Foster, C. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul. Immunol. Inflamm. 2006, 14, 87–90. [Google Scholar] [CrossRef] [PubMed]
- Wakakura, M.; Ishikawa, S. Central serous chorioretinopathy complicating systemic corticosteroid treatment. Br. J. Ophthalmol. 1984, 68, 329–331. [Google Scholar] [CrossRef]
- Gass, J.; Little, H. Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology 1995, 102, 737–747. [Google Scholar] [CrossRef]
- Abu el-Asrar, A. Central serous chorioretinopathy complicating systemic corticosteroid therapy. Eur. J. Ophthalmol. 1997, 7, 297–300. [Google Scholar] [CrossRef]
- Aravind, H.; Rajendran, A.; Baskaran, P.; Lobo, S.; Vempati, J.; Anthony, E. Acute central serous chorioretinopathy following subconjunctival triamcinolone acetonide injection in cataract surgery (less drop approach)—A case series. Indian J. Ophthalmol. 2022, 70, 1066–1068. [Google Scholar]
- Dhanji, S.; Fung, A. Central serous chorioretinopathy secondary to subtenon triamcinolone injection: A new hypothesis for the mechanism. Clin. Exp. Ophthalmol. 2020, 48, 1007–1009. [Google Scholar] [CrossRef]
- O’Brien, P.; Young, R.; Ghafoori, S.; Harper, C.; Wong, R. Central serous retinopathy associated with topical oral corticosteroid use: A case report. J. Med. Case Rep. 2019, 13, 201. [Google Scholar] [CrossRef]
- Zhao, M.; Célérier, I.; Bousquet, E.; Jeanny, J.; Jonet, L.; Savoldelli, M.; Offret, O.; Curan, A.; Farman, N.; Jaisser, F.; et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J. Clin. Investig. 2012, 122, 2672–2679. [Google Scholar] [CrossRef] [PubMed]
- Han, J.; Hwang, J.; Kim, J.; Park, K.; Woo, S. Changes in choroidal thickness after systemic administration of high-dose corticosteroids: A pilot study. Investig. Ophthalmol. Vis. Sci. 2014, 55, 440–445. [Google Scholar] [CrossRef] [PubMed]
- Van Rijssen, T.; van Dijk, E.H.C.; Yzer, S.; Ohno-Matsui, K.; Keunen, J.E.E.; Schlingemann, R.O.; Sivaprasad, S.; Querques, G.; Downes, S.M.; Fauser, S.; et al. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog. Retin. Eye Res. 2019, 73, 100770. [Google Scholar] [CrossRef]
- Yannuzzi, L. Central serous chorioretinopathy: A personal perspective. Am. J. Ophthalmol. 2010, 149, 361–363. [Google Scholar] [CrossRef] [PubMed]
- Chan, W.; Lai, T.; Lai, R.; Liu, D.; Lam, D. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: One-year results of a randomized controlled trial. Ophthalmology 2008, 115, 1756–1765. [Google Scholar] [CrossRef]
- Arora, S.; Sridharan, P.; Arora, T.; Chhabra, M.; Ghosh, B. Subthreshold diode micropulse laser versus observation in acute central serous chorioretinopathy. Clin. Exp. Optom. 2019, 102, 79–85. [Google Scholar] [CrossRef] [Green Version]
- Ghadiali, Q.; Jung, J.; Yu, S.; Patel, S.; Yannuzzi, L. Central serous chorioretinopathy treated with mineralocorticoid antagonists: A one-year pilot study. Retina 2016, 36, 611–618. [Google Scholar] [CrossRef] [PubMed]
ADR Probability Scale | |||||
---|---|---|---|---|---|
To Assess the Adverse Drug Reaction, Please Answer the Following Questionnaire and Give the Pertinent Score | |||||
Yes | No | Do not know | Score | ||
1 | Are there previous conclusive reports on this reaction? | +1 | 0 | 0 | 0 |
2 | Did the adverse event appear after the suspected drug was administered? | +2 | −1 | 0 | 2 |
3 | Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? | +1 | 0 | 0 | 0 |
4 | Did the adverse reaction reappear when the drug was readministered? | +2 | −1 | 0 | 0 |
5 | Are there alternative causes (other than the drug) that could on their own have caused the reaction? | −1 | +2 | 0 | 2 |
6 | Did the reaction reappear when a placebo was given? | −1 | +1 | 0 | 0 |
7 | Was the drug detected in the blood (or other fluid) in concentrations known to be toxic? | +1 | 0 | 0 | 0 |
8 | Was the reaction more severe when the dose was increased, or less severe when the dose was decreased? | +1 | 0 | 0 | 0 |
9 | Did the patient have a similar reaction to the same or similar drug in any previous exposure | +1 | 0 | 0 | 0 |
10 | Was the adverse event confirmed by any objective evidence? | +1 | 0 | 0 | 0 |
Total score | 4 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Han, R.; Xu, G.; Ding, X. COVID-19 Vaccine-Related Vogt–Koyanagi–Harada Disease Complicated by Central Serous Chorioretinopathy during Treatment Course: Case Report and Literature Review. Vaccines 2022, 10, 1792. https://doi.org/10.3390/vaccines10111792
Han R, Xu G, Ding X. COVID-19 Vaccine-Related Vogt–Koyanagi–Harada Disease Complicated by Central Serous Chorioretinopathy during Treatment Course: Case Report and Literature Review. Vaccines. 2022; 10(11):1792. https://doi.org/10.3390/vaccines10111792
Chicago/Turabian StyleHan, Ruyi, Gezhi Xu, and Xinyi Ding. 2022. "COVID-19 Vaccine-Related Vogt–Koyanagi–Harada Disease Complicated by Central Serous Chorioretinopathy during Treatment Course: Case Report and Literature Review" Vaccines 10, no. 11: 1792. https://doi.org/10.3390/vaccines10111792
APA StyleHan, R., Xu, G., & Ding, X. (2022). COVID-19 Vaccine-Related Vogt–Koyanagi–Harada Disease Complicated by Central Serous Chorioretinopathy during Treatment Course: Case Report and Literature Review. Vaccines, 10(11), 1792. https://doi.org/10.3390/vaccines10111792